› $150,000,000 verdict in personal injury case
A cancer treatment drug approved by the Food and Drug Administration (FDA) to treat chronic lymphocytic leukemia and non-Hodgkin’s lymphoma just last year has been linked to a serious adverse reaction known as Stevens Johnson Syndrome, or SJS, when used in conjunction with another medication.
The FDA has approved labeling for a drug to treat chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL), to include a warning of a rare but life-threatening reaction to medication known as toxic epidermal necrolysis, also known as TEN, according to MedScape Today. TEN is the most severe form of Stevens Johnson Syndrome, or SJS, a condition that affects the skin and mucus membranes. Rashes appear on the skin and blister over, causing the skin to peel off in sheets. More than 200 drugs are linked to SJS and TEN, the most common being ibuprofen, antibiotics and anti-seizure medicines. The reported incidence of SJS or TEN is about one case per million people per year.
